期刊文献+

乳腺癌靶向治疗研究进展 被引量:7

Advances in targeted therapy of breast cancer
下载PDF
导出
摘要 乳腺癌的靶向治疗研究已经成为乳腺癌治疗领域研究的热点,是继手术、放疗和化疗三大传统模式之后一种全新的生物治疗模式。分子靶向治疗是指针对乳腺癌发生、发展有关的信号通路及其癌基因相关表达产物进行治疗。本文分别对以HER-2、VEGF、EGFR为靶点及多靶点等4个研究领域的靶向治疗最新进展进行综述。 Currently targeted therapy of breast cancer has become the hot research field and a kind of brand - new biological treatment mode after three traditional pattern of the surgery, radiotherapy and chemotherapy for breast cancer. Molecular targeted therapy is aimed at the occurrence and development of cancer - related signaling pathways and gene expression products. Four research fields on targeted therapy of breast cancer were reviewed in this paper with HER -2 ,VEGF ,EGFR and multiple targets therapy.
出处 《大连医科大学学报》 CAS 2013年第5期496-501,共6页 Journal of Dalian Medical University
关键词 乳腺癌 靶向治疗 进展 breast cancer targeted therapy progress
  • 相关文献

参考文献39

  • 1Baselga J. Treatment of Her2 — overexpressing breast cancer[J]. Ann Oncol,2010,21(7) :vii36 - vii40.
  • 2Alvarez RH. Present and future evolution of advanced breastcancer therapy[ J]. Breast Cancer Res,2010,12(2) :S1.
  • 3Brunelli M,Manfrin E,Martignoni G, et al. HER2/neuassessment in breast cancer using the original FDA and newASCO/CAP guideline recommendations : impact on selec-ting patients for herceptin therapy [ J ]. Am J Clin Pathol,2008,129(6) :907 -911.
  • 4Tahover E,Sonnenblick A, Peretz T,et al. Update: adju-vant trastuzumab in HER2 positive breast cancer[ J]. Hare-fuah,2012,151(1) :37 -42.
  • 5Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatmentwith trastuzumab in HER2 positive breast cancer: resultsfrom the GeparQuattro study [ J ]. J Clin Oncol,2010,28(12):2024-2031.
  • 6Gianni L, Eiermann W, Semiglazov V,et al. Neoadjuvantchemotherapy with trastuzumab followed by adjuvant trastu-zumab versus neoadjuvant chemotherapy alone, in patientswith HER2 positive locally advanced breast cancer ( theNOAH trial) : a randomised controlled superiority trial witha parallel HER2 negative cohort [ J]. Lancet, 2010, 375(9712) :377 -384.
  • 7Perez EA,Romond EH, Suman VJ,et al. Four - year fol-low -up of trastuzumab plus adjuvant chemotherapy for op-erable human epidermal growth factor receptor 2 - positivebreast cancer : joint analysis of data from NCCTG N9831and NSABP B - 31 [ J]. J Clin Oncol, 2011,29 (25):3366 -3373.
  • 8Perez EA, Suman VJ, Davidson NE,et al. Sequential ver-sus concurrent trastuzumab in adjuvant chemotherapy forbreast cancer [ J ]. J Clin Oncol, 2011,29 ( 34 ) : 4491 -4497.
  • 9Gianni L, Dafni U, Gelber RD, et al. Treatment with tras-tuzumab for 1 year after adjuvant chemotherapy in patientswith HER2 - positive early breast cancer : a 4 - yearfollow - up of a randomized controlled trial[ J]. Lancet On-col,2011,12(3) :236-244.
  • 10Jones KL, Buzdar AU. Evolving novel anti - HER2 strate-gies [ J ].Lancet Oncol,2009,10( 12) : 1179.

同被引文献87

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部